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With Normal and Depressed
Left Ventricular Ejection Fraction
Philippe Pibarot, DVM, PHD, Jean G. Dumesnil, MD
Québec City, Québec, Canada
Low-flow, low-gradient (LF-LG) aortic stenosis (AS) may occur with depressed or preserved left ventricular ejec-
tion fraction (LVEF), and both situations are among the most challenging encountered in patients with valvular
heart disease. In both cases, the decrease in gradient relative to AS severity is due to a reduction in transvalvu-
lar flow. The main challenge in patients with depressed LVEF is to distinguish between true severe versus pseu-
dosevere stenosis and to accurately assess the severity of myocardial impairment. Paradoxical LF-LG severe AS
despite a normal LVEF is a recently described entity that is characterized by pronounced LV concentric remodel-
ing, small LV cavity size, and a restrictive physiology leading to impaired LV filling, altered myocardial function,
and worse prognosis. Until recently, this entity was often misdiagnosed, thereby causing underestimation of AS
severity and inappropriate delays for surgery. Hence, the main challenge in these patients is proper diagnosis,
often requiring diagnostic tests other than Doppler echocardiography. The present paper proposes to review the
diagnostic and therapeutic management specificities of LF-LG AS with and without depressed LV
function. (J Am Coll Cardiol 2012;60:1845–53) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.051Severe aortic stenosis (AS) is usually defined on the basis of
both an aortic valve effective orifice area (EOA) 1.0 cm2
and a mean transvalvular gradient 40 mm Hg (1,2).
Nonetheless, given that gradients are a squared function of
flow, even a modest decrease in flow may lead to an
important reduction in gradient, even if the stenosis is very
severe. A low-flow, low-gradient (LF-LG) severe AS in
relation to a decrease in left ventricular ejection fraction
(LVEF) may be observed in approximately 5% to 10% of
patients with severe AS (3,4). Such patients are classically
characterized by a dilated LV with markedly decreased LV
systolic function, most often due to ischemic heart disease
and/or to afterload mismatch (Fig. 1) (5–8). Prognosis is
usually poor (survival rates 50% at 3-year follow-up) if
treated medically, but operative risk is high (6% to 33%) if
treated surgically (3,6–16). Precise assessment of both the
severity of valve stenosis and the degree of myocardial impair-
ment is thus crucial for good therapeutic management.
Recent studies also showed that a “paradoxical” LF-LG
state might nonetheless be observed despite a preserved
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This LF state bears analogy with normal LVEF heart failure
and is, in large part, due to a restrictive physiology whereby
there is pronounced and/or exaggerated myocardial concen-
tric remodeling, small LV cavity size, and reductions in LV
compliance and filling (Fig. 1) (17,18). Proper recognition
of this entity is important because the presence of LG in
conjunction with a normal LVEF may easily lead to an
underestimation of AS severity. The present paper thus
proposes to review the most recent concepts with regards to
the diagnosis and treatment of these 2 challenging entities
(i.e., LF-LG AS with or without preserved LVEF).
For the purpose of this state-of-the-art review, a PubMed
search of the literature was performed using the terms
“aortic stenosis” and “low flow or low gradient or dobut-
amine.” The search was limited to the title and abstract of
full-length articles written in English and published from
1995 to the present. The last update of the search was in
April 2012. This search resulted in 309 articles, 133 of
which were excluded because they were not related to the
targeted topic. Among the remaining 176 articles, 132 were
original articles and 44 were review articles, editorials,
letters, or case reports. To ensure that no potentially
important studies were missed, the reference lists from these
articles were also checked. We then primarily focused on
original studies and multicenter prospective trials that pro-
vided the most robust evidence with regard to diagnosis and
treatment.
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With Low LVEF
Low LVEF, LF-LG severe AS
is generally characterized by the
combination of an EOA 1.0
cm2 or 0.6 cm2/m2 when in-
dexed for body surface area, a low
mean transvalvular gradient (i.e.,
40 mm Hg) and a low LVEF
(40%), causing an LF state.
Several criteria have been pro-
posed in the literature to define
the LF state in AS, including a
cardiac index 3.0 l/min/m2 and
a stroke volume index 35
ml/m2 (2,7,17,26,27). Given that
the gradient essentially depends
on the flow per beat (i.e., the
stroke volume) rather than on
the flow per minute (i.e., the
cardiac output), the former is the
most frequently used parameter
in this context (2,6,17,28,29).
The stroke volume is usually
measured in the LV outflow tract
by Doppler echocardiography
(5–7,16,17,28,29), although it
has also been validated using the
biplane Simpson method and the
thermodilution or green-dye di-
lution methods during cardiac
catheterization (30).
The main diagnostic challenge
in LF-LG AS with low LVEF is
to distinguish true severe from pseudosevere AS. In the
former, the primary culprit is deemed to be the valve disease,
and the LV dysfunction is a secondary or concomitant
phenomenon. Conversely, the predominant factor in pseu-
dosevere AS is deemed to be myocardial disease, and AS
severity is overestimated due to incomplete opening of the
valve in relation to the LF state. Distinction between these
two entities is essential because patients with true severe
AS generally benefit from aortic valve replacement
(AVR), whereas those with pseudosevere AS may not
benefit. Notwithstanding this distinction, operative mor-
tality remains high, ranging between 6% and 33% de-
pending on the presence and/or absence of myocardial
contractile reserve and other comorbidities (3,6 –16). In
particular, a high proportion (46% to 79%) of patients
with low LVEF, LF-LG AS have concomitant coronary
artery disease (CAD) that may negatively impact their
prognosis independently of AS severity (3,7,16). Hence,
identifying which patients may benefit from surgery is
challenging because many variables must be taken onto
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
AS  aortic stenosis
AVR  aortic valve
replacement
BNP  B-type natriuretic
peptide
CAD  coronary artery
disease
CT  computed
tomography
DSE  dobutamine stress
echocardiography
EACT  European
Association for Cardio-
Thoracic Surgery
EOA  aortic valve
effective orifice area
ESC  European Society of
Cardiology
LF-LG  low-flow,
low-gradient
LVEF  left ventricular
ejection fraction
SAVR  surgical aortic
valve replacement
TAVR  transcatheter
aortic valve replacement
Zva  valvulo-arterial
impedanceaccount.Assessment of disease severity and operative risk. DeFil-
ippi et al. (5) were the first to demonstrate that low-dose (up
to 20 g/kg/min) dobutamine stress echocardiography
(DSE) may be used in these patients to assess the presence
of LV flow reserve and to distinguish true versus pseudos-
evere stenosis (Fig. 2). The use of DSE for this purpose
has received a Class IIa (Level of Evidence: B) recom-
mendation in the American College of Cardiology/
American Heart Association-European Society of Car-
diology (ACC/AHA-ESC/EACTS) guidelines (1,2,31),
and a similar protocol has also been used in the cathe-
terization laboratory (30).
ASSESSING LV CONTRACTILE AND/OR FLOW RESERVE.
Patients with no LV flow reserve are defined by a percent increase
in stroke volume20% during DSE (2,7,12,15,16,32) or cathe-
terization (30), and have higher operative mortality (22% to 33%)
than those with flow reserve (5% to 8%) (Figs. 2 and 3). They
epresent approximately 30% to 40% of patients with low LVEF,
F-LG AS (5,7,29–31), and have also been shown to have a
igher prevalence of multivessel CAD (7).
The term “flow reserve” is utilized rather than “contractile
eserve” because several mechanisms not necessarily related
o intrinsic contractility may contribute to the lack of stroke
olume increase during DSE, including: 1) afterload mis-
atch due to an imbalance between the severity of the
tenosis and myocardial reserve (33); 2) inadequate increase
f myocardial blood flow due to associated CAD; and/or
) irreversible myocardial damage due to previous myocar-
ial infarction or extensive myocardial fibrosis. The French
ulticenter Study of LF-LG AS reported that, in patients
ith no LV flow reserve who survived operation, the
ost-operative improvement in LVEF and the late survival
ate were as good as in the patients with flow reserve (12)
nd much better than in those with no flow reserve treated
edically (16) (Fig. 3). Comorbidities such as CAD may
ontribute to the difference between types of treatment, but
nalysis in propensity score–matched cohorts nonetheless
how an independent benefit for AVR (16). When analyzed
ollectively, these findings suggest that the assessment of
V flow reserve by DSE is useful to estimate operative risk
ut does not permit prediction of recovery of LV function,
mprovement in symptomatic status, and late survival after
peration (7,8,12,13,30). Hence, the absence of LV flow
eserve should not preclude consideration of AVR in these
atients (7,16).
DISTINGUISHING BETWEEN TRUE SEVERE AND PSEUDO-
SEVERE AS. The evaluation of the changes in EOA and
gradient during dobutamine infusion are also helpful in
differentiating true severe from pseudosevere AS. Typically,
pseudosevere AS shows an increase in EOA and relatively
little increase in gradient in response to increasing flow,
whereas true severe AS is characterized by little or no
increase in EOA and an increase in gradient that is
congruent with the relative increase in flow (Fig. 2). Several
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ature to identify patients with pseudosevere AS during
DSE, including a peak stress mean gradient 30 or 40
mm Hg depending on studies, a peak stress EOA 1.0 or
1.2 cm2, and/or an absolute increase in EOA 0.3 cm2
(2,5–7,30,34) (Fig. 2); thus, the optimal cutoff values
remain to be determined. The prevalence of pseudosevere
AS is reported to be between 20% and 30% (5,28–30,35).
Some patients may nonetheless have an ambiguous
response to DSE (e.g., a peak gradient of 29 mm Hg and
an EOA of 0.8 cm2) due to variable increases in flow
(5,28,29), and interpreting the changes in EOA and
gradients without considering the relative changes in flow
may often be problematic. Hence, to overcome this
limitation, the investigators of the TOPAS (Truly or
Pseudo-Severe Aortic Stenosis) study proposed to calcu-
late the projected EOA that would have occurred at a
standardized flow rate of 250 ml/s (EOAProj) (28,29)
(Fig. 4), and this new parameter has been shown to be
more closely related to actual AS severity, impairment of
Figure 1 Different Patterns of Severe AS According to Flow, Gr
The majority (50% to 70%) of patients with severe aortic stenosis (AS) develop lef
allows maintenance of normal LV pump function. These patients with severe AS a
sical” low-flow, low-gradient (LF-LG) AS (5% to 10% of the AS population) generally
reduced LV outflow. Normal LVEF, “paradoxical” LF-LG AS (10% to 25% of AS popu
and a restrictive physiology leading to impaired LV filling, altered myocardial functi
doxical LF may present with a LG despite presence of severe stenosis. AVA  aor
flow rate (in square centimeters); Ca  calcium score (in Agatston units); CABG 
mean transvalvular gradient (in mm Hg); SAVR  surgical aortic valve replacement
tion by Craig Skaggs.myocardial blood flow, LV flow reserve, and survival than Athe traditional DSE parameters (8,28,29,36). The full
potential of the EOAProj remains to be determined by
uture studies (Fig. 2).
Patients with no increase in stroke volume may nonethe-
ess have an increase in mean flow rate sufficient to allow a
eliable measurement of EOAProj; this is due to shortening
of LV ejection time in relation to an increase in heart rate
(Fig. 2) (28,29). However, there are 10% to 20% of patients
in whom the increase in flow rate is insufficient to allow
calculation of EOAProj (28,29). In such cases or those with
ambiguous results during DSE, quantification of valve
calcification by multislice computed tomography may also
be useful (Fig. 2). Cueff et al. (37) suggested that a score
1,650 Agatston units provides good accuracy to distin-
guish true severe from pseudosevere AS.
ASSESSING PROGNOSIS AND OPERATIVE RISK. In the subset
f low LVEF, LF-LG AS patients treated medically,
orbidity and mortality risk factors identified in previous
tudies were reduced functional capacity as assessed by Duke
t, and LV Geometry
icular (LV) hypertrophy with normal LV cavity size and ejection fraction (EF), which
mal transvalvular flow rate exhibit a high gradient. Patients with low LVEF, “clas-
dilated LV cavity with markedly depressed myocardial systolic function and
) is characterized by pronounced LV concentric remodeling, small LV cavity size
d reduced LV outflow. Because of the LF state, patients with classical or para-
e area (in square centimeters); AVAproj  projected aortic valve area at normal
ary artery bypass graft; CT  computed tomography; Op.  operative; P 
stroke volume; TAVR  transcatheter aortic valve replacement. Figure illustra-adien
t ventr
nd nor
have a
lation
on, an
tic valv
coron
; SV ctivity Score Index (20) or by 6-min walk test
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Low-Flow, Low-Gradient Aortic Stenosis November 6, 2012:1845–53(320 m), presence of CAD, more severe stenosis as
assessed by EOAProj 1.2 cm
2, and reduced peak stress
VEF (35%) (8,16,29,35). A high plasma B-type natri-
retic peptide (BNP) level (550 pg/ml) would also appear
o be a powerful predictor of mortality in patients with
Figure 2 Clinical Decision Making Process in Low LVEF, LF-LG
Dobutamine stress echocardiography (DSE) is useful to assess LV flow reserve an
calcification by multislice computed tomography (CT) may also be used to corrobo
that need to be further validated. EOA  effective orifice area. (in square centimet
transvalvular gradient (in mm Hg); Ca  calcium score (in Agatston Unit); SV  st
catheter aortic valve replacement; other abbreviations as in Figure 1. *Cutoffpoint
illustration by Craig Skaggs.
Figure 3
Survival of Patients With Low LVEF,
LF-LG AS According to Presence of
LV Flow Reserve and Type of Treatment
Patients with no LV flow (contractile) reserve (Group II) defined as 20% increase
in stroke volume during DSE have markedly reduced survival compared with those
with LV flow reserve (Group I), regardless of the type of treatment. Aortic valve
replacement is associated with dramatic improvement in survival in patients with
LV flow reserve and a trend for better survival in those with no flow reserve. *p 
0.001 versus medical; § p  0.07 versus medical. Adapted with permission from
Monin et al. (7).F-LG AS regardless of treatment (medical vs. surgical) or
he presence and/or absence of flow reserve (13).
In the subset of low LVEF, LF-LG patients who
nderwent AVR, the most powerful operative mortality risk
actors were absence of LV flow reserve, very low pre-
perative resting mean gradient (20 mm Hg), multivessel
re AS
istinguish between the true severe and pseudosevere AS. Quantification of valve
enosis severity. Text between parentheses represents new emerging parameters
OAProj  projected EOA at normal flow rate (in square centimeters); P  mean
lume; Op. operative; SAVR  surgical aortic valve replacement; TAVR  trans-
vary depending on studies. † See text for explanation and references. Figure
Figure 4
Calculation of Projected EOA at
Normal Flow Rate (EOAProj) to Distinguish
Between True Severe and Pseudosevere AS
The projected aortic valve area (EOAProj) extrapolates what the EOA would be at a
standardized normal flow rate (Q) of 250 ml/s. Yellow circles depict the values of
EOA as a function of Q at each stage of the DSE. The valve compliance (VC) is the
slope of the regression line (blue line), which is calculated by dividing the maximal
increase in EOA (0.15 cm2) by the maximal increase in Q (70 ml) during DSE.
In this case, there was a discordance between peak stress EOA (0.85 cm2) and
peak stress gradient (35 mm Hg) during DSE, but the EOAProj (0.97 cm
2; pink cir-
cle) confirmed that the stenosis was severe. Abbreviations as in Figures 1 and 2.Seve
d to d
rate st
ers); E
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The intriguing inverse relationship between baseline gradi-
ent and operative mortality is probably due to the fact that
a very LG is a composite marker for a less severe or
pseudosevere stenosis and/or a more pronounced impair-
ment of intrinsic myocardial function. Also, these patients
are known to be more vulnerable than patients with normal
LVEF to the excess in LV load caused by patient–prosthesis
mismatch (4,38); therefore, a particular effort should be
made to avoid this eventuality.
The predictors of late mortality after AVR are higher
EuroSCORE (European System for Cardiac Operative
Risk Evaluation), previous atrial fibrillation, multivessel
CAD, low pre-operative gradient, high plasma levels of
BNP, and patient–prosthesis mismatch (4,7,15). Although
data are limited, some studies also reported that AVR and
concomitant coronary artery revascularization both had
independent beneficial effects on survival (8,14). Other
factors reported as also having a significant impact on
outcome and response to treatment were the degree of
myocardial viability and, conversely, the extent of myocar-
dial fibrosis (22,39,40). Reversibility of myocardial fibrosis
following AVR likely depends on its type (reactive intersti-
tial vs. replacement) and extent (mild vs. severe) as well as
extent of correction of its causal mechanism (i.e., pressure
overload and/or myocardial ischemia) (41). A recent study
(22) reported more extensive myocardial fibrosis in patients
with both types of LF-LG AS compared with patients with
normal flow, high-gradient AS (Fig. 5). Furthermore,
Figure 5 Relation Between Myocardial Fibrosis, LV Longitudina
(A) The degree of myocardial fibrosis measured by biopsy at the time of valve rep
those with paradoxical LF-LG (red triangles) compared with those with normal flow
documented by mitral ring displacement is inversely related to the degree of myoc
placement, a surrogate marker of myocardial fibrosis, and can be used to differen
sion for Herrmann et al. (22).longitudinal myocardial shortening was affected to a largerextent in these patients with LF-LG AS due to more
advanced fibrosis in the subendocardial layer, where fibers
are oriented longitudinally (42). Better standardization and
validation are, however, necessary before quantification of
myocardial fibrosis by magnetic resonance imaging can be
implemented clinically (41).
Therapeutic management. The ACC/AHA guidelines
(1) provide no specific recommendation for the treatment of
patients with low LVEF, LF-LG AS, whereas the ESC/
EACTS guidelines (2) support the utilization of AVR
(Class IIa; Level of Evidence: C) in the subset of patients
with LV flow reserve. Nonetheless, there presently appears
to be a clear consensus that patients with true severe AS and
evidence of “LV flow” reserve should be considered for AVR
and that coronary artery bypass graft surgery should be
performed concomitantly whenever necessary.
The evidence, albeit limited, is however not as clear in
patients with LV flow reserve and pseudosevere AS because
prognosis appears to be poor, whatever the treatment
(7,30,32,35). Hence, such patients should probably be
treated medically at first, but nonetheless followed up very
closely (i.e., every 2 to 3 months), and the therapeutic
options reconsidered in case of lack of improvement or
deterioration (Fig. 2) (35). The outcome of these patients is
largely determined by the extent of the imbalance between
the degree of myocardial impairment and the degree of AS
severity. Hence, although moderate AS may be well toler-
ated by a normally functioning ventricle, it may have the
same impact as a severe stenosis in a failing ventricle. This
rtening, and Hemodynamic Load
nt is more pronounced in patients with low LVEF, LF-LG (black open circles) and
gradient (blue open squares) severe AS. Also, the LV longitudinal shortening as
fibrosis. (B) The valvulo-arterial impedance correlates well with mitral ring dis-
F-LG severe versus moderate (green open losanges) AS. Reprinted with permis-l Sho
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Low-Flow, Low-Gradient Aortic Stenosis November 6, 2012:1845–53patients with pseudosevere AS have a better prognosis if
treated surgically rather than medically (7,29,30,35). To this
effect, the cutoff values of EOA 1.0 cm2 or mean gradient
40 mm Hg found in the guidelines were originally derived
from series of patients with preserved LVEF, and it is
possible that less stringent cutoff values (e.g., EOA or
EOAProj 1.2 cm
2 and mean gradient 30 to 35 mm Hg)
ould be more appropriate for patients with decreased
VEF (29,30,35) (Fig. 2). AS severity is only one half of the
quation, the other half being the degree of myocardial
mpairment which, for a given degree of AS severity, may
ary considerably from one patient to the other, to the
xtent that, in selected cases with severe myocardial impair-
ent, heart transplantation might also become an option.
inally, failure of medical therapy could also be due to a
orsening of AS severity during follow-up, in which case
VR should be reconsidered.
Patients with no LV flow reserve are an equally challeng-
ng group with regard to diagnosis and treatment. AVR can
ertainly be contemplated in patients with evidence of a true
evere AS on DSE or computed tomography (CT) (Fig.2)
37). As for the DSE parameters, it is possible that the
utoff value of CT valve calcium score used to define severe
S may also have to be adapted (i.e., lowered down from
,650 to 1,200 Agatston units), because as outlined
reviously, what is moderate stenosis for a normal ventricle
ay correspond to a severe stenosis for a diseased ventricle.
n the ESC/EACTS guidelines (2), AVR received a Class
Ib (Level of Evidence: C) recommendation for patients
ith low LVEF, LF-LG AS, and no LV flow reserve.
iven that operative risk for open heart surgery is generally
ery high in absence of flow reserve, transcatheter AVR
TAVR) could provide a valuable alternative in these
atients, although the rates of morbidity and mortality may
e higher than in patients with normal flow (43–45).
ecent studies reported a greater and more rapid improve-
ent of LVEF in patients treated by TAVR than those
reated by surgical AVR (43,45). This advantage is believed
o be related to better myocardial protection as well as to a
esser incidence of patient–prosthesis mismatch. In contrast,
AVR is associated with a higher incidence of paravalvular
egurgitation, which may eventually have a negative impact
n outcomes. Obviously, further randomized studies com-
aring surgery versus TAVR in LF-LG AS patients are
arranted.
ow-Flow, Low-Gradient AS With Normal LVEF
previous paradigm was that patients with severe AS and
reserved LVEF should necessarily have a high transvalvu-
ar gradient. However, Hachicha et al. (17) reported that a
ubstantial proportion of patients with severe AS on the
asis of EOA1.0 cm2 and/or indexed EOA0.6 cm2/m2
might develop a restrictive physiology, resulting in low
cardiac output (i.e., stroke volume index 35 ml/m2) and
ower than expected transvalvular gradients (i.e., 40 mm Hg)espite the presence of a preserved LVEF (i.e., 50%); this
linical entity was labeled “paradoxical” LF-LG AS (Fig. 1)
17,18).
athophysiology and clinical presentation of paradoxical
F-LG AS. Paradoxical LF-LG AS shares many patho-
hysiological and clinical similarities with normal LVEF
eart failure (17,18,20). The prevalence of these entities
ncreases with older age, female gender, and concomitant
resence of systemic arterial hypertension. Both entities are
lso characterized by a restrictive physiology, whereby LV
ump function and thus stroke volume are markedly re-
uced despite a preserved LVEF. The distinctive features of
his entity are: 1) more pronounced LV concentric remod-
ling and myocardial fibrosis both contributing to reduce
he size, compliance, and filling of the LV (Fig. 1); and 2)
marked reduction in intrinsic LV systolic function, not
videnced by the LVEF, but rather by other more sensitive
arameters directly measuring LV mid-wall or longitudinal
xis shortening. In particular, longitudinal shortening is
educed to a larger extent in these patients due to more
dvanced fibrosis in the subendocardial layer (Fig. 5)
17,20–22,24,25,39,46). These findings are consistent with
ore advanced stages of both valvular and ventricular
iseases despite the normal LVEF. Several studies reported
hat these patients have a worse prognosis than those with
oderate AS or normal flow severe AS (17,24,47).
The distinctive mode of presentation of this entity often
omplicates the assessment of AS severity and therapeutic
ecision making. Patients with paradoxical LF-LG are
haracterized by similar or worse EOA and Doppler velocity
ndex than patients with normal flow, but yet their gradients
re lower than what would be expected in these circum-
tances (17,18). Moreover, the LF state may also cause these
atients to have normal blood pressure levels despite a reduced
ystemic arterial compliance and/or an increased vascular re-
istance due to a phenomenon of pseudonormalization (17,18).
ence, both the valvular and arterial hemodynamic burdens
ay appear artificially low, whereas several studies reported
hat the level of global LV hemodynamic load, as measured by
alvulo-arterial impedance (Zva), is consistently much higher
han that observed in patients with normal flow severe AS
Fig. 5) (17,20–22,24,25,48,49).
itfalls and differential diagnosis. Patients with paradox-
cal LF-LG AS should always be distinguished from pa-
ients with severe AS based on EOA 1.0 cm2 and LG
(i.e., 40 mm Hg) but normal flow (i.e., stroke volume
index 35 ml/m2) (18). In the latter, the features of
restrictive physiology or of a marked increase in Zva are
conspicuously absent (18,24,25,50), and the discordance
between EOA and gradient may be explained by one or
more of the following (18,23): 1) measurement errors: that
is, underestimation of stroke volume and AVA and/or
underestimation of gradient; 2) small body size: AS severity
may be overestimated in a patient with a small body surface
area if EOA is not indexed for body surface area; and
3) inherent inconsistencies in the guidelines criteria
p
t
D
c
t
o
c
a
a
L
p
m
v
i
t
b
t
p
d
T
L
o
s
1851JACC Vol. 60, No. 19, 2012 Pibarot and Dumesnil
November 6, 2012:1845–53 Low-Flow, Low-Gradient Aortic Stenosis(18,23,51): theoretical models have shown that a patient
with normal transvalvular flow rate and an EOA of 1.0 cm2
should be expected to have a mean gradient around 30 to 35
mm Hg rather than the 40 mm Hg cutoff value given in the
guidelines (1,2).
Notwithstanding measurement errors, the distinction be-
tween the two conditions is important given that, among
patients with EOA 1.0 cm2, patients with bona fide
aradoxical LF-LG AS have the worse prognosis, whereas
hose with normal flow and LG have the best (18,24,50).
ifferential diagnosis can be made by indexing the EOA, by
onfronting measurements of stroke volume and EOA with
hose obtained by other independent methods (e.g., Teich-
lz, 2- or 3-dimensional volumetric methods using echo-
ardiography or cardiac magnetic resonance imaging) (52),
nd by searching for the other typical features usually
ssociated with paradoxical LF-LG AS.
Another caveat is that, as in patients with low-LVEF,
F-LG AS, the LF state may nonetheless conceal a
seudosevere stenosis. As in patients with low LVEF,
easurements of EOA and gradient during DSE and of
alve calcification by multidetector CT might prove useful
n this regard. The clinical relevance of pseudosevere AS in
he context of paradoxical LF-LG AS, however, remains to
e determined and should be approached with circumspec-
ion, given that these patients nonetheless have a restrictive
hysiology with low cardiac output, high global LV hemo-
ynamic load, and a poor prognosis (18).
herapeutic management and outcome. PARADOXICAL
OW-FLOW, LOW-GRADIENT AS. In the current 2006 ACC/
AHA guidelines (1,2), there is no specific recommendation
for the management of patients with paradoxical LF-LG
Figure 6 Impact of AVR on Survival in Patients With Paradoxic
The data for the (A) entire cohort (n  101) and (B) propensity score matched pa
Reprinted from The Annals of Thoracic Surgery, Volume 91(6), Tarantini G, Covolo
lar gradient and left ventricular ejection fraction exceeding 0.50, 1808–1815, 201AS, given that this is a new entity first described in 2007(17). A class IIa recommendation for AVR in the patients
with paradoxical LF-LG and evidence of severe AS is
however included in the recent ESC/EACTS guidelines
(2). Nonetheless, the mode of presentation of this entity is
most challenging given that the EOA is consistent with
severe AS and thus constitutes a Class I indication for AVR
when the patient is symptomatic, whereas the LG in
association with a normal LVEF would rather suggest a
moderate AS warranting conservative therapy. Accordingly,
previous studies reported that the referral rate for surgery is
40% to 50% lower in patients with paradoxical LF-LG
severe AS than in patients with normal flow severe AS,
which is likely due to an underestimation of AS severity in
light of the LG (17,19,48,53). However, these patients
clearly have a better prognosis if treated surgically (Fig. 6)
(14,18,48,53–55), although they could theoretically be at
higher operative risk given their myocardial impairment and
their increased risk of having patient–prosthesis mismatch
due to their small LV cavity (18,22,24,25,48,56). The
advantage of surgery is still present when other variables
such as CAD are taken into account by performing propen-
sity score–matched analysis (Fig. 6B). It remains to be
determined if TAVR could not be a better alternative in
these patients.
NORMAL-FLOW, LOW-GRADIENT AS. As mentioned previ-
usly, patients with preserved LVEF, normal flow, LG but
mall EOA (often between 0.8 and 1.0 cm2) are generally
patients with moderate-to-severe AS who have an EOA–
gradient discordance due to an inherent inconsistency in the
guidelines criteria and/or to a small body size. In a recent
substudy of the SEAS (Simvastatin and Ezetimibe in Aortic
-LG AS
(n  61). AVR  aortic valve replacement; other abbreviations as in Figure 1.
zolini R, et al. Valve replacement for severe aortic stenosis with low transvalvu-
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1, witStenosis) trial, Jander et al. (50) reported that patients with
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prognosis compared with those with moderate AS. How-
ever, these patients were an heterogeneous group, likely
comprising without distinction patients with bona fide
paradoxical LF AS and patients with normal-flow, LG AS
in conjunction with measurement error, small body size,
and/or inconsistencies due to the guidelines criteria (57).
Moreover, the weighing of each entity within the whole
group could have influenced the results given that, among
patients with EOA 1.0 cm2, the former were found to
ave the worse prognosis and the latter the best prognosis
24). These observations further underline the importance
f making a meticulous differential diagnosis when seeing a
atient with LG severe AS despite a preserved LVEF, and
n particular, to validate the stroke volume measurements
nd to search for other features usually associated with
aradoxical LF AS (i.e., small LV with restrictive physiol-
gy, unequivocally high Zva, and so on).
Conclusions
LF-LG AS with either normal or reduced LVEF is among
the most challenging of situations encountered in patients
with valvular heart disease. DSE greatly aids risk stratifica-
tion and clinical decision making in patients with low
LVEF, LF-LG AS. Valve calcium quantification by mul-
tidetector CT and measurement of plasma BNP may also be
helpful for the management of these patients, especially in
those with no LV flow reserve in whom DSE is often
inconclusive.
Paradoxical LF-LG AS despite normal LVEF is a
recently described entity that has been shown to be associ-
ated with a more advanced stage of the disease and worse
prognosis. Hence, it must be properly identified, and in
particular, it must be differentiated from other confounding
situations, including measurement errors, small body size,
and discrepancies due to the inherent inconsistencies in the
guideline criteria.
TAVR may eventually prove to be an attractive alterna-
tive to surgical AVR in both types of LF-LG severe AS, but
this remains to be confirmed by future randomized studies.
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